Navigation Links
Health risks after cessation of postmenopausal hormone therapy
Date:3/4/2008

The Womens Health Initiative (WHI) investigators have produced another article [1], which probably marks the opening of another set of publications, in which the consequences of a further 2.4-year follow-up (after cessation of the study medication) on the estrogen + progestogen (E + P) cohort are reported. They concluded that, by the end of the post-intervention period, the global index, a newly formed and unvalidated tool used in the WHI trial, was still higher in women randomly assigned to receive E + P compared with placebo.

After such long and painful debates over the results of the WHI study and the perception that age is a very important determinant of the benefitrisk evaluation, it is really a pity that once again the current information on the extended follow-up period is presented in an unsatisfactory way, says Professor Amos Pines, the President of the International Menopause Society. It seems that the following mistakes were repeated:

  1. There is no mention of the results by age groups and yet, for the age group 5059 years, the data recorded for the active phase of the WHI E + P arm showed no significant increase in risk of coronary events, strokes and breast cancer in the early postmenopause period. Also, there is no breakdown of the data by years of follow-up. It would be extremely important to know whether the results for the first year post cessation of therapy are similar to those for year 2 and year 3 of follow-up.
  2. The breast cancer results for first-time users of E + P were not presented, whereas breast cancer risk during the active phase of the WHI was similar to that of the placebo group in women with no prior use of E + P.
  3. There is little relevance in the presentation of the combined results for the active phase and the follow-up phase, since it has no real scientific importance. Combining the two periods and grouping the outcomes (all cancers, all cardiovascular events) helped the authors to show significance in some of the variables. However, the overall differences in the annualized rates between the E + P arm and the placebo arm were in the order of 1.5 cardiovascular events per 1000 women/year and 1.2 cancers per 1000 women/year. Again, no data were shown for the younger age group.

It seems that the WHI investigators have forgotten the turmoil and anxiety they caused in 2002 when they published the preliminary results of the E + P cohort, concluded Professor Pines. By releasing the new data without performing all the necessary, important sub-analyses, women could face another unjustified turmoil related to hormone therapy.


'/>"/>

Contact: Dr. David Sturdee
david.sturdee@btinternet.com
International Menopause Society
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology: